MAP2K7 and cancer: As of this writing, Cancer Council Australia and ESMO have not reviewed the emerging immunotherapy literature, or the clinical trials with BRAF and/or MEK inhibitors for patients with BRAF V600E ([v-raf murine sarcoma viral oncogene homolog B1] valine at amino acid 600) mutations; this Expert Panel is aware of this (see Future Directions).